A placebo controlled, randomized, double-blind phase II clinical trial to evaluate tolerability, safety and efficacy endpoints after administration of recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 (rhIGF-I/rhIGFBP-3) [mecasermin rinfabate] for 24 weeks in adults with myotonic dystrophy type 1
Latest Information Update: 11 Jan 2022
At a glance
- Drugs Mecasermin rinfabate (Primary)
- Indications Muscular dystrophies; Myotonic dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Insmed
- 08 Dec 2021 Primary endpoints are amended.
- 08 Dec 2021 Status changed from active, no longer recruiting to completed.
- 21 Jul 2008 Trial now fully enrolled according to Insmed media release.